When to use a z-test vs t-test vs chi-square vs ANOVA

In healthcare, “Can we randomize it?” is the wrong first question. Start with “Could either experience change care, rights, privacy, or access?”

A/B testing can improve digital intake, appointment access, patient education, clinician workflows, and administrative operations. It can also create unacceptable risk when teams treat a clinical or consent decision like an ordinary conversion funnel.

The difference is not the label on the method. A/B tests are randomized experiments. What matters is the treatment, purpose, affected population, data flow, and oversight required in the organization and jurisdiction. This guide provides a practical product framework, not a substitute for legal, clinical, privacy, security, or institutional review.

Draw the boundary before designing variants

Create an intake step that classifies the proposed change before anyone builds a treatment. At minimum, ask:

• Can the change alter diagnosis, treatment, triage, dosage, or clinical recommendations?
• Can it delay or discourage access to care, accommodations, or urgent help?
• Does it change informed consent, privacy choice, required disclosure, or patient cost?
• Does it use protected or sensitive health information for assignment or measurement?
• Does it include children, people in crisis, or another population requiring added protection?
• Is the purpose internal quality improvement, or is it designed to contribute to generalizable knowledge?
• Could the software function fall within medical-device or clinical decision-support oversight?

The HHS quality-improvement guidance says many activities limited to improving patient care and collecting operational data are not research under the cited human-subjects regulations. It also states that some quality-improvement activities can have a research purpose, in which case human-subject protections may apply. A product team should not make that determination informally; route it to the organization’s authorized office.

Likewise, software that influences clinical decisions is not automatically an ordinary product surface. The FDA’s January 2026 clinical decision-support guidance explains that some software functions are excluded from the device definition while other patient- or caregiver-facing functions can remain subject to digital-health policy. Clinical and regulatory owners need to classify the function before experimentation.

Start with lower-risk operational questions

The safest early program tests reversible changes where both variants meet the same clinical, accessibility, privacy, and disclosure requirements.

Appointment reminder timing

Compare 2 approved reminder schedules or message structures to reduce missed appointments. Keep required details, opt-out behavior, language support, and urgent-contact instructions constant.

Use completed appointments or timely rescheduling as the primary outcome. Track cancellations, patient contacts, message delivery, opt-outs, wrong-recipient risk, and differences across language, age, disability, or access groups. A higher click rate is not enough if no-show rates or trust worsen.

Patient portal navigation

Test whether a clearer information architecture helps people complete a high-value administrative task, such as finding results, updating insurance, or sending a non-urgent message. Preserve emergency guidance and clinical escalation paths in both variants.

Measure successful task completion and time to completion. Guard against repeated navigation, abandonment, accessibility failures, mistaken message routing, and increased call-center burden. Use usability testing before the A/B test to catch failures randomization should never expose.

Administrative form sequence

Compare a long form with a staged flow, or test the order of non-clinical fields. Do not omit information needed for safe care, billing transparency, consent, or legal compliance.

Measure accurate completion, not just submission. Track validation errors, correction rates, staff rework, abandonment, and time to appointment. If the treatment collects sensitive data, confirm necessity and access controls before launch.

Educational content layout

Test 2 ways to present the same clinician-approved information: summary-first versus stepwise, text plus illustration versus text alone, or a clear action checklist versus a dense paragraph. Keep the medical meaning, risks, contraindications, and escalation advice equivalent.

Use a comprehension or appropriate next-action metric when feasible. Page time and clicks can be misleading. Accessibility, language quality, and comprehension across health-literacy levels belong in the guardrail plan.

Review the design before launch

Use a trustworthy experiment-design session to pressure-test metrics, safety checks, and decision rules before exposing patients or clinicians.

Watch the Experiment Design Session

Use stronger controls for care-adjacent products

Some product changes are not clinical interventions but can still influence care. They need clinical ownership, narrower eligibility, conservative ramps, and explicit stopping criteria.

Clinician workflow support

A test might compare how a work queue prioritizes administrative follow-up, how a note template reduces documentation work, or how a non-diagnostic alert is presented. The treatment should not silently alter the clinical standard of care.

Randomize at the unit that prevents contamination. Individual clinician assignment may fail when teams share queues and handoffs; clinic- or unit-level clusters may better match the workflow. Measure task completion and time saved, with guardrails for missed work, overrides, escalations, documentation quality, and staff workload.

Preventive-care outreach

Compare approved outreach content or channels for people already eligible under the same clinical rule. Do not experiment with whether one group receives necessary care or required notice.

Use completed appropriate follow-up as the primary outcome. Track opt-outs, unreachable patients, scheduling capacity, disparities, complaints, and downstream cancellations. If the treatment drives demand beyond operational capacity, a messaging lift can make access worse.

Digital adherence support

Test the presentation or timing of an approved reminder, checklist, or educational cue. Avoid treatment changes that could be interpreted as personalized medical advice without the corresponding validation and oversight.

Measure the intended behavior with caution. Self-reported completion or app engagement is not a clinical outcome. Include adverse-event reporting, escalation pathways, disengagement, and privacy events where relevant.

Feature rollout in health software

Use feature flags to separate deployment from release, start with internal or trained cohorts, and expand only when technical and clinical guardrails remain healthy. GrowthBook’s feature flag platform supports targeted rollouts and kill switches, while the experiment layer measures impact.

The rollback plan must describe more than turning off a flag. Determine whether the old experience remains clinically and operationally safe, how queued work is reconciled, what happens to partial workflows, and who is authorized to stop exposure.

Protect data by design

Do not send a broad event stream to an experimentation vendor and decide later which fields were unnecessary. Inventory the data before implementation:

The HHS minimum-necessary guidance describes limiting uses, disclosures, and requests for protected health information to what is needed for the intended purpose, with policies based on roles and recurring versus non-routine access. Apply that principle to experiment attributes, debugging logs, dashboards, and downloaded readouts.

Pseudonymous identifiers reduce exposure but do not automatically make a dataset non-sensitive or outside applicable rules. Review linkability, small cohorts, free-text fields, URLs, device metadata, and combinations that can reveal a condition. Never put clinical details or identifiers in feature names, variation labels, or URLs.

A warehouse-native experimentation approach can query approved metrics where the organization already governs them. Architecture does not create compliance on its own; teams still need contracts, access control, auditability, retention rules, security review, and configuration that matches the approved data flow.

Keep unsafe questions out of product experimentation

An experimentation policy should name prohibited or separately governed categories. Product teams should not discover the boundary only after a proposal reaches launch review.

Do not use an ordinary product A/B test to withhold a clinically indicated service, emergency direction, safety warning, accessibility accommodation, required disclosure, or legally protected choice. Do not reduce the visibility of risks to improve completion. Do not randomize a diagnostic or treatment recommendation without the clinical, regulatory, and research framework appropriate to that intervention.

Avoid treatments that exploit fear, urgency, shame, or uncertainty about health. A message can increase appointment conversion while undermining informed choice. Likewise, do not test whether patients tolerate a harder cancellation, more confusing privacy control, or hidden cost. Both variants must meet the organization’s baseline standard for respectful and comprehensible communication.

Clinical AI and decision-support changes need an evaluation program beyond a click-based A/B test. Validate the model offline, examine performance and failure modes across relevant populations, review human factors, and stage deployment with clinical monitoring. An online comparison may contribute evidence only after both treatments meet the safety threshold for exposure.

When an activity may be human-subjects research, follow the institution’s process before enrolling or exposing anyone. HHS research-oversight training states that covered non-exempt human-subjects research requires the applicable review and that informed consent requirements apply unless the IRB authorizes otherwise. The product team should preserve the determination, protocol version, approved treatment, and reporting obligations with the experiment record.

Finally, do not interpret lack of detected harm as proof of safety. Rare adverse events, small vulnerable groups, and outcomes that occur after the experiment window may be underpowered. Use prior evidence, incident monitoring, qualitative reports, and post-rollout surveillance alongside the randomized estimate.

Define patient-centered metrics and guardrails

Healthcare teams need more than a conversion scorecard. Build a measurement hierarchy:

1. Primary outcome: the operational or patient-facing result that answers the decision.
2. Process diagnostics: steps that explain why the treatment worked or failed.
3. Safety guardrails: outcomes that trigger a stop or clinical review.
4. Equity checks: predeclared groups where access or benefit could differ.
5. Operational guardrails: staffing, wait time, rework, cost, and downstream capacity.

Define the practical threshold before launch. A statistically detectable change may be too small to justify implementation, and a neutral aggregate can hide meaningful harm in a protected or vulnerable group. At the same time, slicing results across many small subgroups increases false-positive risk and can expose sensitive attributes. Predeclare the equity questions that matter and use appropriate privacy and multiple-testing controls.

GrowthBook supports reusable fact tables and metrics so teams can keep definitions reviewable. Use a power analysis for the primary outcome and critical guardrails. If the required sample or duration is unrealistic, do not weaken the standard; use usability research, simulation, staged quality improvement, or a larger treatment contrast.

Create a healthcare experiment review packet

Before launch, the owner should provide one reviewable packet:

• purpose, hypothesis, and operational decision
• classification and required oversight determination
• affected population and exclusion criteria
• clinical, privacy, security, accessibility, and compliance approvals
• treatment screenshots or workflow diagrams
• assignment, exposure, and data-flow design
• primary outcome, diagnostics, guardrails, and equity checks
• sample plan and stopping rule
• rollout stages, monitoring owner, and rollback procedure
• patient or clinician communication plan, if applicable
• documentation and retention plan

Use an approval matrix that names accountable people. Product approval does not replace clinical approval; a privacy review does not settle human-subjects research status; and an IRB determination does not automatically approve the production security architecture.

The WHO clinical-trial best-practices guidance emphasizes ethical standards, regulatory considerations, patient-centered research, transparency, and stakeholder collaboration. Not every healthcare product experiment is a clinical trial, but high-risk work should inherit the same respect for people and evidence.

Build trust into the experimentation program

Start with reversible operational improvements where both experiences are already acceptable. Prove that the team can classify risk, minimize data, validate assignment, monitor safety, and document decisions before expanding scope.

Publish internal rules for what teams may test, what requires added review, and what is out of bounds. Maintain an experiment registry and audit trail. Record neutral and negative results so a new team does not repeat the same risky idea.

GrowthBook can support the controlled delivery and analysis layer through experimentation, feature flags, permissions, and warehouse-defined metrics. The organization remains responsible for the clinical, ethical, legal, privacy, and operational framework around every test.

In healthcare, speed is valuable only when the learning process protects the people whose behavior creates the data.

Build a governed test workflow

Connect controlled releases to reviewable metrics and decision rules while keeping healthcare data in your approved architecture.

Get Started With GrowthBook

An experiment with control plus three variants creates more than one comparison. ANOVA gives the team one principled global test of whether the variants differ before it starts hunting for a winner.

Analysis of variance, or ANOVA, is a family of statistical models for comparing group means and decomposing sources of variation. In a one-way product experiment, the “factor” is the assigned variant and its “levels” are control, B, C, and D.

The basic ANOVA question is deliberately broad: if all variants had the same population mean, would the observed separation among their sample means be surprising relative to the noise within variants?

That question is useful, but incomplete. A significant ANOVA result does not say which variant won, whether the lift is large enough to ship, or whether assumptions and instrumentation are sound. Those conclusions require planned contrasts, uncertainty intervals, and experiment-quality checks.

How ANOVA compares means through variance

ANOVA separates total variability into components:

• between-group variation: how far each group mean is from the overall mean
• within-group variation: how far individual observations are from their group mean

Each sum of squares is divided by its degrees of freedom to produce a mean square. The F statistic is:

F = mean square between groups / mean square within groups

Under the null hypothesis that all group means are equal, both quantities estimate the same underlying error variance, so their ratio should often be near 1. When group means are separated relative to the residual noise, F grows.

NIST's one-way ANOVA explanation describes this as comparing the level mean square with the residual mean square. The p-value is the probability, under the null model and assumptions, of an F statistic at least as large as the observed one.

For k groups and N total observations, one-way ANOVA usually has:

between-group degrees of freedom = k - 1
within-group degrees of freedom = N - k

The numerator asks how much the k means vary. The denominator pools information about variability inside the groups.

A four-variant experiment example

Suppose a SaaS team tests four onboarding flows and measures projects created per eligible account during the first week.

The null hypothesis is:

mean_control = mean_B = mean_C = mean_D

The alternative is that not all four means are equal. Notice what it does not say: “C is best.” The global alternative includes any pattern where at least one mean differs.

If the F-test rejects the null, the team should evaluate the comparisons it planned. It might compare every treatment with control, or test one contrast between the current flow and the average of three new concepts. The comparison plan should reflect the decision, not the visual ranking in the finished dashboard.

Make multiple tests trustworthy

See how experimentation leaders plan hypotheses, guardrails, and review practices when a result surface contains many possible claims.

Watch the Trustworthy Experiments Talk

Why not run every pairwise t-test?

Four groups create six pairs. If the team runs six independent tests at alpha 0.05 and treats any significant result as proof, the probability of at least one false positive across the family can exceed 0.05.

ANOVA gives one global test of the equality of all means. It also estimates residual variation using all groups, which can be more efficient than estimating it afresh for each pair under the classical equal-variance model.

The global test does not eliminate multiplicity in follow-up comparisons. R's Tukey HSD documentation explicitly notes that ordinary t-tests inflate the probability of a false declaration across a family. Choose the follow-up procedure for the comparisons the decision actually needs:

• every pair: Tukey-style simultaneous comparisons
• every treatment versus control: Dunnett-style comparisons
• a few planned product questions: predeclared contrasts with a suitable adjustment
• a conservative small family: a Bonferroni or Holm correction

An omnibus test can also be nonsignificant while one carefully planned contrast is persuasive, because the hypotheses and power differ. Decide before launch whether the global null or a treatment-versus-control contrast is the primary decision test.

Unequal group sizes do not automatically invalidate ANOVA, but they make the variance assumption and contrast plan more consequential. If allocation is intentionally uneven, power the smallest comparison that drives the decision and preserve the assignment probabilities. When variances and sample sizes both differ, classical pooled ANOVA can behave poorly; Welch ANOVA or a regression with suitable standard errors is usually easier to defend.

Planned contrasts can also use product structure that the global test ignores. Instead of comparing every pair, a team might compare control with the average of three related treatments, or compare two low-intensity treatments with two high-intensity treatments. A small set of predeclared contrasts often answers the business question with more power and clearer multiplicity control than an exhaustive winner search.

ANOVA assumptions in experiments

The familiar one-way fixed-effects model can be written as:

outcome = overall mean + variant effect + residual error

Classical inference depends on the residuals and design, not on a requirement that the combined raw outcome form one bell curve. NIST's model reference assumes independent, normally distributed errors with mean zero and common variance.

Independent observations

The analysis unit must respect randomization. If accounts are assigned but every user within an account is treated as independent, the standard error ignores clustering. Aggregate at the account level or use cluster-robust or hierarchical methods.

Repeated events from one user create the same problem. Ten sessions from one user do not carry the same independent information as ten users.

Appropriate residual behavior

ANOVA is often robust to moderate non-normality with balanced, sufficiently large groups, but severe skew, outliers, censoring, or zero inflation can make the mean unstable or the F approximation unreliable. Diagnose residuals and assess whether the mean is still the business estimand.

Equal variance for classical one-way ANOVA

Classical ANOVA assumes a common population variance. This can fail when a treatment changes both the mean and spread, or when groups serve different traffic mixes. Unequal group sizes make the problem more consequential.

SciPy's 0 supports Welch ANOVA when equal_var=False. Welch's method relaxes equal population variances and adjusts the degrees of freedom.

Correct outcome model

ANOVA targets a continuous mean. Conversion is binary; event counts are discrete; time-to-churn can be censored. Large-sample mean inference can sometimes work, but logistic, Poisson or negative-binomial, survival, or other generalized models may better represent the outcome and produce interpretable effects.

One-way, two-way, and repeated-measures ANOVA

“ANOVA” names a family rather than one calculation.

One-way ANOVA

One categorical factor with multiple levels, such as four assigned onboarding variants. This is the usual A/B/n example.

Two-way or factorial ANOVA

Two controlled factors, such as headline and layout. The model estimates each main effect plus their interaction. The interaction asks whether one factor's effect changes with the other. This is central to a properly designed multivariate test.

Repeated-measures ANOVA

The same units are observed under multiple conditions or times. Dependence is part of the design and must be modeled. A basic independent one-way ANOVA is invalid for repeated measurements.

ANCOVA

Analysis of covariance adds continuous covariates to the group comparison. In randomized experiments, pre-experiment covariates can improve precision when they are chosen and measured without post-treatment contamination. GrowthBook's guide to variance reduction explains the same motivation in online experimentation.

Run one-way ANOVA in Python

At the action boundary, keep one numeric observation per independent analysis unit in each group. In SciPy:

from scipy.stats import f_oneway

control = [2, 1, 4, 3, 2, 2, 5]
variant_b = [3, 2, 4, 4, 3, 2, 5]
variant_c = [4, 3, 5, 4, 4, 3, 6]

# Classical one-way ANOVA: assumes equal population variances.
result = f_oneway(control, variant_b, variant_c, equal_var=True)
print(result.statistic, result.pvalue)

# Welch ANOVA: does not assume equal population variances.
welch = f_oneway(control, variant_b, variant_c, equal_var=False)
print(welch.statistic, welch.pvalue)

Before running it, confirm that rows match the randomization unit and missing values have a documented policy. Afterward, inspect group summaries and residual behavior. The p-value alone cannot reveal a broken exposure join or a few enormous outliers.

In R, aov(outcome ~ variant, data = experiment) fits the classical model. R documents 1 as a linear-model interface, which helps explain why ANOVA, regression, and contrasts are closely connected.

Interpret the ANOVA table

A standard output contains:

• degrees of freedom
• sum of squares
• mean square
• F statistic
• p-value

Suppose the output reports F(3, 4016) = 6.8, p < 0.001. Under the model, the observed ratio of between-variant to within-variant variation is unlikely if all four population means are equal. It does not mean every treatment beats control or that any effect is commercially important.

Add the quantities the product decision needs:

• each mean and sample size
• differences from control in original units
• simultaneous or comparison-specific intervals
• an effect-size measure when useful
• guardrail and data-quality results
• the follow-up comparison method

Avoid ranking noisy means without uncertainty. The highest observed variant has benefited from both its true effect and sampling variation, especially when many variants were screened.

Common ANOVA mistakes

Treating events as independent users

Repeated events make the nominal sample size huge and uncertainty too narrow. Preserve the assignment unit.

Using ANOVA for every metric shape

The word “variant” does not imply ANOVA. Match the outcome distribution and estimand to a model.

Checking assumptions after selecting a winner

Write the model, outlier policy, transformation, and variance choice before the ranking is visible. Result-driven switching creates hidden researcher degrees of freedom.

Treating a significant F-test as a winner declaration

Follow with the planned contrasts. The omnibus test only rejects equality of all means.

Ignoring practical significance

A very large experiment can detect a tiny difference. Compare intervals with a minimum practical effect and account for implementation cost and guardrails.

Use ANOVA as part of an experiment plan

Before launch, specify the factor and levels, independent unit, primary continuous outcome, minimum effect, sample-size plan, variance assumption, global or contrast hypothesis, comparison family, and stopping rule.

Then verify assignment and exposure before interpreting the model. A sample ratio mismatch can signal that observed group counts no longer reflect the planned randomization. No F-test can repair biased exposure data.

ANOVA is valuable because it turns a field of variant means into a structured model of signal and noise. The broader z-test, t-test, chi-square, and ANOVA guide shows when the outcome and hypothesis call for another member of that family. Use the omnibus test for the global question, planned contrasts for the decision, and effect estimates for practical judgment. That sequence makes a multiple-variant test easier to defend than a dashboard full of uncoordinated p-values.

Compare variants with discipline

Run controlled experiments, connect trusted metrics, and review treatment effects and uncertainty in one shared workflow.

Start With GrowthBook

A mobile treatment can improve activation and still be unsafe to ship. A small crash increase, a slower launch, or a broken older app version can erase the apparent win.

Mobile A/B testing has the same causal goal as web experimentation: randomly assign eligible participants and compare outcomes. The operating environment is less forgiving. Users keep old binaries, lose connectivity, switch devices, deny permissions, and receive releases through app-store review and staged rollout systems.

The 10 tests below cover acquisition, first value, repeated use, monetization, and performance. Each pattern includes the outcome worth measuring and the mobile-specific guardrails that protect product quality.

Design for versions, devices, and delayed updates

Before selecting a test, define the population precisely. “All mobile users” can contain several app versions, OS releases, device classes, countries, and identity states. A treatment implemented only in the newest binary cannot be assigned safely to an older one.

Record these fields in the experiment contract:

• minimum and maximum supported app version
• operating system and device eligibility
• assignment identifier and persistence behavior
• offline fallback and cached value behavior
• exposure event and retry rules
• primary, diagnostic, and guardrail metrics
• kill switch, owner, and rollback threshold

Use an SDK-supported feature assignment rather than inventing a local random value for each screen. GrowthBook provides client and mobile SDK documentation for deterministic feature evaluation. The experiment-design workflow also recommends treating platform and app version as explicit eligibility dimensions.

App-store beta testing and product experimentation solve different problems. Apple positions TestFlight as a way to collect feedback on prerelease builds. Google Play offers internal, closed, and open testing tracks before or alongside production releases. Use those channels to find defects and compatibility problems; use a randomized production experiment to estimate behavioral impact in the intended population.

Test acquisition and first value

The first 4 tests ask whether the right users install the app and reach a meaningful outcome after opening it.

1. Test the store listing promise

Compare an icon, screenshot sequence, feature graphic, or description that represents a distinct user motivation. The app-store test answers an acquisition question: which truthful promise causes more qualified people to install or open the app?

Measure store conversion, first open, activation, and early retention where data can be joined lawfully. An install lift with lower activation may mean the new creative overpromises. Google Play’s official store-listing experiment workflow supports localized text and graphics experiments, target metrics, minimum detectable effects, and confidence settings.

2. Test onboarding length and order

Compare a focused path to first value with a more explanatory sequence, or change which setup step comes first. The mechanism should identify the uncertainty being removed: unfamiliar terminology, too many choices, or a dependency users discover too late.

Use activation as the primary metric. Track completion by step, time to value, errors, skips, week-1 return, and support requests. Keep assignment stable after an app restart so a user does not enter a different sequence halfway through.

3. Test the permission request moment

Compare asking for a permission at launch with asking at the moment its value becomes clear. Do not manipulate the permission explanation or block unrelated product use.

Measure successful completion of the permission-dependent task, not the acceptance rate alone. Track denial, later settings changes, abandonment, and crashes. The control and treatment must both comply with platform policy and present an accurate reason for access.

4. Test the empty state

Compare a generic empty screen with a context-specific starting action, sample content, or import path. This tests whether the product can help someone create the first useful object without requiring prior knowledge of the information architecture.

Measure successful creation and subsequent use. Track sample deletion, failed imports, and whether users mistake placeholder data for their own. If the app works offline, verify that the treatment degrades cleanly without network access.

Tie mobile tests to value

Choose primary, diagnostic, and guardrail metrics that connect each in-app change to activation and durable use.

Read the KPI Playbook

Improve repeated product use

These tests target the workflows users perform after activation. Because existing users have learned the current interface, examine novelty and adaptation rather than interpreting the first day as the permanent effect.

5. Test navigation around the top task

Compare 2 coherent navigation models, such as promoting a core action into the primary tab bar or consolidating secondary destinations. Avoid changing several unrelated features and calling the bundle a navigation test.

Use completed top tasks as the primary outcome. Track backtracking, search, screen depth, accessibility behavior, and errors. Segment new and established users in advance because experienced users may slow down temporarily when controls move.

6. Test the return surface

Compare the default launch destination: a dashboard, the last active object, an inbox, or a next-best action. The hypothesis should reflect the product’s usage rhythm. A daily operations app and a monthly reporting app should not optimize the same return behavior.

Measure successful session outcomes and repeat use. Track cold-start time, stale cached content, failed deep links, and offline behavior. Do not use session length as a universal success metric; a faster task can shorten sessions while improving the experience.

7. Test notification timing or content

Hold timing constant when testing message content, and hold content constant when testing timing. A notification should surface relevant value, status, or required action rather than create artificial urgency.

Measure the completed in-app task attributable to the message. Track opt-outs, disabled permissions, complaints, duplicate delivery, and retention. Avoid randomizing at send time if eligibility or assignment can change between scheduling and delivery.

Apple’s review-prompt guidance illustrates the same contextual principle: make a request after a successful sequence and avoid interrupting the task. A review prompt is not a normal engagement CTA, and the platform limits how often the system displays it.

Test monetization and performance carefully

Commercial and technical tests can have large impact, but they also create the strongest asymmetry: a small conversion lift may not justify billing confusion, instability, or long-term churn.

8. Test a paywall’s value explanation

Compare how the paywall explains a real product boundary, such as advanced capabilities, collaboration, or usage. Keep prices, trial terms, and eligibility constant when the experiment is about communication.

Use paid conversion or revenue per eligible user as the primary metric. Track refunds, cancellations, trial retention, support contacts, and store-review sentiment. If the treatment changes prices rather than presentation, use the platform’s supported pricing experiment path and account for existing subscribers.

Google Play’s price-experiment guidance reports revenue and confidence intervals and advises waiting for statistical significance before applying a variant. The product team still needs to evaluate retention and customer impact outside the immediate store result.

9. Test a high-cost feature or algorithm

Compare a new feed, search, sync, media, or AI behavior with the current implementation. The outcome may be task success, quality, or retention, but the guardrails must capture compute, latency, battery, network, and failure behavior.

Roll out gradually and keep a remote kill switch. Analyze effects by device capability and app version when the mechanism suggests they differ. A treatment that works on recent flagship phones can still be unsuitable for the supported population.

10. Test startup and interaction performance

Treat a performance optimization as a product experiment when it changes user-visible behavior or resource use. Compare the optimized path with the current one under stable assignment and measure both performance and customer outcomes.

Use startup time, interaction latency, and successful task completion. Track crash, app-not-responding, memory, battery, and network metrics. Android vitals identifies user-perceived crash rate, ANR rate, wake locks, and memory as core quality measures that can affect store visibility.

Research on mobile performance experiments warns that app-performance metrics have measurement pitfalls. A device may contribute many observations, metrics can be highly skewed, and aggregation choices can change the conclusion. Plan analysis at the appropriate user or device level instead of treating every timing event as independent.

Keep assignments stable across the app lifecycle

Mobile identity changes over time. A person can open anonymously, create an account, reinstall, restore a backup, or use a second device. Define which behavior is correct for the treatment.

Log the feature value, experiment identifier, app version, and relevant platform context with the exposure. Deduplicate or aggregate repeated events according to the metric definition. A user who opens the app 50 times is not 50 independent users.

Run a sample ratio mismatch check and compare exposure volumes with eligible active users. Version-specific missing events, a failed configuration fetch, or a platform-only crash can create allocation imbalance. Investigate the pipeline before reading the outcome.

Use feature flags and experimentation together: the flag controls which behavior runs, while the experiment estimates the effect. Keep the default value safe when the network is unavailable, and test both variants in automated and manual release QA.

Use guardrails as release criteria

A mobile test should have numeric rollback conditions, not a vague instruction to “watch crashes.” Define the acceptable change in crash rate, ANR, startup time, error rate, and any product-specific safety metric. Make the condition sensitive enough to catch meaningful harm in the ramp population.

The initial release path can be staged:

1. Validate both variants internally and in beta tracks.
2. Release the binary with the treatment off by default.
3. Start with a small eligible production cohort.
4. Confirm assignment, exposure, and guardrail telemetry.
5. Expand according to the ramp plan.
6. Stop, roll back, or continue to the powered decision point.

This sequence is operational control, not a substitute for statistical design. Plan sample size with a power analysis, specify the stopping rule, and report effect sizes with uncertainty. When product leaders need frequent result checks, use a valid sequential testing method.

Build a mobile learning loop

Start with one mobile-specific customer problem and choose the test pattern that matches it. Define eligible versions and devices, persist assignment, and measure exposure only after the treatment is available. Pair the product outcome with stability and performance guardrails.

After the decision, implement the winner as maintained app behavior, remove the obsolete branch, and monitor the rollout by version and device. Archive a readout that states what changed, who was included, what the effect was, and where uncertainty remains.

GrowthBook supports warehouse-native experiment analysis and feature evaluation across application surfaces. That combination lets mobile teams join app exposure with activation, subscription, retention, and support outcomes while keeping the release controlled through a flag.

Ship mobile tests with control

Use feature flags, shared metrics, and staged exposure to test mobile changes without tying the decision to one app release.

Get Started With GrowthBook